MAR 3 1 2003 AV

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Gommissioner of Patents, Washington, D.C. 20231 on March 12003

Caroline Wei-Berk 45.203

Maine of Attorney/Agent Registration No.

Signature of Attorney or Agent

P&G Case 7987

Confirmation No. 1705

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Andrew John Fagg

Serial No. 09/813,252 : Group Art Unit 1751

Filed March 20, 2002 : Examiner Not Yet Assigned

For FABRIC BAG FOR USE IN FABRIC CARE PROCESSES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

APR 0 2 7003

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. [X] 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1^{st} O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

- (a) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that <u>both</u> a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.
- (b) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.
- (C) The Notification of Acceptance of this Application Under 35 U.S.C. §371 does <u>not</u> indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.
- 4. [] 37 C.F.R. §1.97 (b)(4) (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. [] <u>Information to be Considered with CPA Filing</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6.	[]	37 C.F.I	R. §1.97(c)	with fee pay	ment	(use after	1 st Of	fice	Action	& be	efore
Fina	l Office A	ction or l	Notice of A	llowance)							
	This in	formation	disclosure	statement is	being	submitted	under	37	C.F.R.	§1.97	/(c).
Appl	icant(s) h	ave not red	ceived a fina	al action unde	r 37 C.I	F.R. §1.113	, a noti	ce of	f allowa	nce ur	nder
25.0	ED 010	. 1 1					na amm1	iaati	on (o a	Evn	arta

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) Copies of the cited references were previously cited by or submitted to the USPTO
in prior application Case No, U.S. Patent Application Serial No, filed Applicants
claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents
are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).
OR
[X] (2) Copies of the cited documents are enclosed.
OR
[] (3) Copies of all said documents, except document No.'s, were submitted
and considered in parent application U.S. Patent Application Serial No, filed
Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly,
copies of document No.'s are not provided with this Statement, pursuant
to 37 C.F.R. §1.98(d). Copies of document No.'s are enclosed. It is
respectfully requested that the cited documents be carefully considered by the Examiner and
made of record in this case.
(4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
reference that is not in the English language is provided.
Total control in the English ranguage is provided.
(5) Applicants also respectfully request the Examiner to consider and make of record
the copending applications listed on the attached page.
+

[]Additional information is attached.

Respectfully submitted,

Caroline Wei-Berk

Attorney or Agent for Applicant(s)

Registration No. 45,203

(513) 627-0352

Date: March 24, 2002

Customer No. 27752

(IDS.doc) (Last Revised 5/21/02)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTQ TRADE

(use as many sheets as necessary)

SHEET 1 of 1

COMPL	ETE IF KNOWN
Application Number	09/813,252
Confirmation Number	1705
Filing Date	March 20, 2002
First Named Inventor	Andrew John Fagg et al.
Group Art Unit	1751
Examiner Name	Not yet Assigned
Attorney Docket Number	7987

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-6,381,870 B1	05/07/2002	Kohlman et al.	
		US-2002/0112365 A1	08/22/2002	Kohlman et al.	صحب مدد وزر براز
		US-			ال وي د د د د د د د د د د د د د د د د د د
		US-			400 no 2002 —
		US-			
	1	US-		F1	
		US-		C.	
	t	US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DO Country Code ³ Number ⁴	CUMENT Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	_						
	-						
							
	ļ						
							
	<u> </u>						
		1					L

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T⁰
EXAMINE	₹	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.